Source: Alex Lavoie
Leerink Partners Stand by Certara Inc. with “Outperform” Rating
Leerink Partners, a prominent investment firm, recently reaffirmed its “Outperform” rating for Certara Inc. (NASDAQ:CERT). The company’s stock is currently priced at around $6.39. Certara is a leading entity in the Medical – Biomedical and Genetics industry, renowned for its innovative software and services aimed at accelerating drug development. This rating from Leerink Partners, as disseminated by StreetInsider, suggests that investors should maintain their holdings in Certara’s stock despite the company’s recent earnings report.
Certara’s Quarterly Earnings Report
Certara’s most recent earnings report revealed a quarterly earnings per share (EPS) of $0.09, a figure that fell short of the Zacks Consensus Estimate of $0.11. This indicates a 20.57% negative surprise and a decrease from the EPS of $0.15 posted in the same quarter of the previous year. Such a development may raise concerns among some investors, however, it’s important to note that Certara has managed to exceed consensus EPS estimates twice in the past four quarters, demonstrating the potential for future growth.
Revenue Performance
Despite the shortfall in EPS, Certara’s revenue performance paints a more positive picture. The company declared a quarterly revenue of $103.65 million for the quarter ending in December 2025. This slightly beat the Zacks Consensus Estimate by 0.41%, representing a step up from the $100.36 million reported in the same period the previous year. Over the last year, Certara has surpassed consensus revenue estimates three times out of four, suggesting consistent performance in its operations and a potential for continued growth.
Current Stock Performance
As of now, Certara’s stock is trading at $6.61, indicating a slight increase of 0.23% or $0.015. The stock has seen a daily low of $6.04 and a high of $6.66. Over the past year, the stock has experienced a peak of $15.38 and a low of $6.04. This fluctuation reflects the volatility of the stock market, which is influenced by a variety of factors, including the overall health of the economy, investor sentiment, and company-specific news.
Certara boasts a market capitalization of approximately $1.05 billion, with a trading volume of 2,780,555 shares. Market capitalization, also known as market cap, is a measure of a company’s total market value, calculated by multiplying the total number of shares by the current share price. It provides investors with an idea of the size of the company and how it compares with other companies in the same industry.
Conclusion: A Promising Outlook
Despite the recent miss on the EPS front, Leerink Partners’ continued “Outperform” rating for Certara suggests a positive outlook. The company’s revenue performance over the past four quarters and its consistent surpassing of estimates is a promising sign for potential investors. The growth of the Medical – Biomedical and Genetics industry, combined with Certara’s innovative solutions for drug development, also points towards a promising future for the company. Investors are advised to keep an eye on the company’s performance and consider the larger picture when making investment decisions.